Pulmonary Embolism Center

TRUST Pivotal Study of Innova Laguna Thrombectomy System Completes Enrollment

September 1, 2026—Innova Vascular, Inc. announced the completion of patient enrollment in the TRUST pivotal investigational device exemption clinical study, which is evaluating the safety and effectiveness of the company’s Laguna thrombectomy system for the treatment of pulmonary embolism (PE).

The PERT Consortium CEO Michelle Lanno to Step Down at Year’s End

July 20, 2026—Michelle Lanno, Chief Executive Officer of The PERT Consortium, announced she will be stepping down from her role effective December 31, concluding more than a decade of leadership that began with the organization’s founding in 2015.

SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

ENGULF Analysis Shows Reduced Blood Loss With E2’s Hēlo System in PE Procedures

May 4, 2026—A comparative analysis from the ENGULF trial demonstrated that using blood return during continuous aspiration thrombectomy dramatically reduced blood loss by 97%, while maintaining hemodynamic efficacy and improving procedural efficiency.

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

Mermaid’s Angel Catheter Approved in Europe for Pulmonary Embolism Prevention

April 10, 2026—Mermaid Medical Group announced that the company’s Angel catheter has received European CE Mark approval for the prevention of pulmonary embolism.

HI-PEITHO: Boston Scientific’s Ekos System Superior to Anticoagulation Alone in Acute Intermediate-Risk PE

March 28, 2026—Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endovascular system in patients with intermediate-risk pulmonary embolism (PE) met the composite primary endpoint.

Thrombolex Secures Financing for Commercialization of Bashir Catheters for Pulmonary Embolism Treatment

March 17, 2026—Thrombolex, Inc., a commercial-stage developer of a differentiated pharmacomechanical lysis platform for the treatment of pulmonary embolism and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed and supported by current investors and cofounders.

AHA/ACC Issue First Acute PE Guidelines With New Clinical Classification System

February 20, 2026—The American College of Cardiology (ACC)/American Heart Association (AHA) Joint Committee on Clinical Practice Guidelines and eight other professional societies released their first joint clinical practice guideline dedicated to the evaluation and management of acute pulmonary embolism (PE) in adults, introducing a new severity-based classification system and comprehensive recommendations spanning diagnosis, treatment, and follow-up care.

ALPHA-PE Research Fund Launched to Advance Pulmonary Embolism Care

February 5, 2026—AngioDynamics, Inc. and The PERT Consortium announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism (PE) research.

Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients

December 16, 2025—Penumbra announced the publication of a new study that showed that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) technology for intermediate-risk pulmonary embolism (PE) may shorten length of hospital stay, reduce complications, and improve discharge outcomes without increasing mortality compared to other treatment modalities.